In this respect, SRIF and octreotide, a sst2-preferring agonist, reduced apoptosis as well as VEGF expression and release in retinal explants exposed to stressors similar to those characterizing diabetic retinopathy, that is, high glucose, oxidative stress, or advanced glycation end-products [129,130]. Here, VEGFA is linked to diabetic retinopathy.